Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G/A
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2
(Amendment No. 1)*
Tetraphase Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
88165N105
(CUSIP Number)
December 31, 2014
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
¨ Rule 13d-1(c)
x Rule 13d-1(d)
* | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures previously provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (the Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
13G/A
CUSIP No. 88165N105 | Page 2 of 19 Pages |
1. | Names of reporting persons
Mediphase Venture Partners II Limited Partnership | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
Delaware | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
760,209 shares | |||||
7. | Sole dispositive power
0 shares | |||||
8. | Shared dispositive power
760,209 shares | |||||
9. |
Aggregate amount beneficially owned by each reporting person
760,209 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
2.48%(1) | |||||
12. | Type of reporting person (see instructions)
PN |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 3 of 19 Pages |
1. | Names of reporting persons
Mediphase Venture Partners II (Annex Fund) Limited Partnership | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
Delaware | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
245,153 shares | |||||
7. | Sole dispositive power
0 shares | |||||
8. | Shared dispositive power
245,153 shares | |||||
9. |
Aggregate amount beneficially owned by each reporting person
245,153 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
0.80%(1) | |||||
12. | Type of reporting person (see instructions)
PN |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 4 of 19 Pages |
1. | Names of reporting persons
Mediphase Venture Partners (DP & UP) Limited Partnership | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
Delaware | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
396,808 shares | |||||
7. | Sole dispositive power
0 shares | |||||
8. | Shared dispositive power
396,808 shares | |||||
9. |
Aggregate amount beneficially owned by each reporting person
396,808 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
1.29%(1) | |||||
12. | Type of reporting person (see instructions)
PN |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 5 of 19 Pages |
1. | Names of reporting persons
Mediphase Venture Partners II (Select Fund) Limited Partnership | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
Delaware | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
99,191 shares | |||||
7. | Sole dispositive power
0 shares | |||||
8. | Shared dispositive power
99,191 shares | |||||
9. |
Aggregate amount beneficially owned by each reporting person
99,191 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
0.32%(1) | |||||
12. | Type of reporting person (see instructions)
PN |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 6 of 19 Pages |
1. | Names of reporting persons
Mediphase II LLC | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
Delaware | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
760,209 shares | |||||
7. | Sole dispositive power
0 shares |
|||||
8. | Shared dispositive power
760,209 shares | |||||
9. |
Aggregate amount beneficially owned by each reporting person
760,209 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
2.48%(1) | |||||
12. | Type of reporting person (see instructions)
OO |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 7 of 19 Pages |
1. | Names of reporting persons
Mediphase II (Annex Fund) LLC | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
Delaware | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
245,153 shares | |||||
7. | Sole dispositive power
0 shares | |||||
8. | Shared dispositive power
245,153 shares | |||||
9. |
Aggregate amount beneficially owned by each reporting person
245,153 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
0.80%(1) | |||||
12. | Type of reporting person (see instructions)
OO |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 8 of 19 Pages |
1. | Names of reporting persons
Mediphase (DP & UP) LLC | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
Delaware | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
396,808 shares | |||||
7. | Sole dispositive power
0 shares | |||||
8. | Shared dispositive power
396,808 shares | |||||
9. |
Aggregate amount beneficially owned by each reporting person
396,808 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
1.29%(1) | |||||
12. | Type of reporting person (see instructions)
OO |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 9 of 19 Pages |
1. | Names of reporting persons
Mediphase II (Select Fund) LLC | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
Delaware | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
99,191 shares | |||||
7. | Sole dispositive power
0 shares | |||||
8. | Shared dispositive power
99,191 shares | |||||
9. |
Aggregate amount beneficially owned by each reporting person
99,191 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
0.32%(1) | |||||
12. | Type of reporting person (see instructions)
OO |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 10 of 19 Pages |
1. | Names of reporting persons
Lawrence Miller | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
United States | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
1,501,361 shares | |||||
7. | Sole dispositive power
0 shares | |||||
8. | Shared dispositive power
1,501,361 shares | |||||
9. |
Aggregate amount beneficially owned by each reporting person
1,501,361 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
4.89%(1) | |||||
12. | Type of reporting person (see instructions)
IN |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 11 of 19 Pages |
1. | Names of reporting persons
Paul Howard | |||||
2. | Check the appropriate box if a member of a group (see instructions) (a) ¨ (b) ¨
| |||||
3. | SEC use only
| |||||
4. | Citizenship or place of organization
United States | |||||
Number of shares beneficially owned by each reporting person with |
5. | Sole voting power
0 shares | ||||
6. | Shared voting power
1,501,361 shares | |||||
7. | Sole dispositive power
0 shares | |||||
8. | font> | Shared dispositive power
1,501,361 shares | ||||
9. |
Aggregate amount beneficially owned by each reporting person
1,501,361 shares | |||||
10. | Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
| |||||
11. | Percent of class represented by amount in Row 9
4.89% (1) | |||||
12. | Type of reporting person (see instructions)
IN |
(1) | Based on the Reporting Persons holdings as of January 31, 2015, this percentage is calculated based upon 30,657,532 shares of the Common Stock outstanding as of November 4, 2014 as set forth in the Issuers most recent Form 10-Q for the period ending September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014. |
13G/A
CUSIP No. 88165N105 | Page 12 of 19 Pages |
Explanatory Note: This Amendment No. 1 amends, supplements and restates (as applicable) the statement on Schedule 13G that was filed with the Securities and Exchange Commission (the SEC) on February 13, 2014 (the Original Filing) and relates to the Reporting Persons (as defined in Item 2(a) of the Original Filing) beneficial ownership interest in the common stock, par value $0.001 per share (the Common Stock), of Tetraphase Pharmaceuticals, Inc., a Delaware corporation (the Issuer). Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms used but not otherwise defined herein have the meanings assigned to such terms in the Original Filing.
This Amendment No. 1 constitutes an exit filing for the Reporting Persons, whose aggregate beneficial ownership has fallen below 5.0%.
Item 1. |
(a) | Name of Issuer: | |
Tetraphase Pharmaceuticals, Inc. | ||
(b) | Address of Issuers Principal Executive Offices: | |
There are no amendments to Item 1(b) of the Original Filing. |
Item 2(a). | Name of Person Filing: |
There are no amendments to Item 2(a) of the Original Filing. |
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
There are no amendments to Item 2(b) of the Original Filing. |
Item 2(c). | Citizenship: |
There are no amendments to Item 2(c) of the Original Filing. |
Item 2(d). | Title of Class of Securities: |
This Amendment No. 1 to Schedule 13G report relates to the Common Stock of Tetraphase Pharmaceuticals, Inc. |
Item 2(e). | CUSIP Number: |
88165N105 |
13G/A
CUSIP No. 88165N105 | Page 13 of 19 Pages |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not Applicable. |
Item 4. | Ownership |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. |
A. | Mediphase Venture Partners II Limited Partnership |
(a) | Amount beneficially owned:
As of January 31, 2015, MVP II LP was the record and beneficial owner of 760,209 shares of the Issuers Common Stock (the MVP II LP Record Shares). | |||||
(b) | Percent of class:
MVP II LPs ownership of the MVP II LP Record Shares represented a beneficial ownership interest of approximately 2.48% of the outstanding shares of the Issuers Common Stock as of January 31, 2015. | |||||
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 760,209 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 760,209 |
B. | Mediphase Venture Partners II (Annex Fund) Limited Partnership |
(a) | Amount beneficially owned:
As of January 31, 2015, MVP II Annex LP was the record and beneficial owner of 245,153 shares of the Issuers Common Stock (the MVP II Annex Record Shares). | |||||
(b) | Percent of class:
MVP II Annex LPs ownership of the MVP II Annex Record Shares represented a beneficial ownership interest of approximately 0.80% of the outstanding shares of the Issuers Common Stock as of January 31, 2015. | |||||
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 245,153 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 245,153 |
13G/A
CUSIP No. 88165N105 | Page 14 of 19 Pages |
C. | Mediphase Venture Partners (DP & UP) Limited Partnership |
(a) | Amount beneficially owned:
As of January 31, 2015, MVP DP&UP LP was the record and beneficial owner of 396,808 shares of the Issuers Common Stock (the MVP DP&UP Record Shares). | |||||
(b) | Percent of class:
MVP DP&UP LPs ownership of the MVP DP&UP Record Shares represented a beneficial ownership interest of approximately 1.29% of the outstanding shares of the Issuers Common Stock as of January 31, 2015. | |||||
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 396,808 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 396,808 |
D. | Mediphase Venture Partners II (Select Fund) Limited Partnership |
(a) | Amount beneficially owned:
As of January 31, 2015, MVP II Select LP was the record and beneficial owner of 99,191 shares of the Issuers Common Stock (the MVP II Select Record Shares& #x94;). | |||||
(b) | Percent of class:
MVP II Select LPs ownership of the MVP II Select Record Shares represented a beneficial ownership interest of approximately 0.32% of the outstanding shares of the Issuers Common Stock as of January 31, 2015. | |||||
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 99,191 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 99,191 |
E. | Mediphase II LLC |
(a)/(b) | Amount beneficially owned:
In its capacity as general partner of MVP II LP, Mediphase II LLC may be deemed to be the beneficial owner of the MVP II LP Record Shares, representing a beneficial ownership of approximately 2.48% of the Issuers Common Stock. |
13G/A
CUSIP No. 88165N105 | Page 15 of 19 Pages |
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 760,209 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 760,209 |
F. | Mediphase II (Annex Fund) LLC |
(a)/(b) | Amount beneficially owned:
In its capacity as general partner of MVP II Annex LP, Annex II LLC may be deemed to be the beneficial owner of the MVP II Annex Record Shares, representing a beneficial ownership of approximately 0.80% of the Issuers Common Stock. | |||||
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 245,153 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 245,153 |
G. | Mediphase (DP & UP) LLC |
(a)/(b) | Amount beneficially owned:
In its capacity as general partner of MVP DP&UP LP, DP&UP LLC may be deemed to be the beneficial owner of the MVP DP&UP Record Shares, representing a beneficial ownership of approximately 1.29% of the Issuers Common Stock. | |||||
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 396,808 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 396,808 |
H. | Mediphase (Select Fund) LLC |
(a)/(b) | Amount beneficially owned:
In its capacity as general partner of MVP II Select LP, Select Fund LLC may be deemed to be the beneficial owner of the MVP II Select Record Shares, representing a beneficial ownership of approximately 0.32% of the Issuers Common Stock. |
13G/A
CUSIP No. 88165N105 | Page 16 of 19 Pages |
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 99,191 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 99,191 |
I. | Lawrence Miller |
(a)/(b) | Amount beneficially owned:
In his capacity as a manager of each of Mediphase II LLC, Annex II LLC, DP&UP LLC, and Select Fund LLC, Mr. Miller may be deemed to be the beneficial owner of the MVP II LP Record Shares, the MVP II Annex Record Shares, the MVP DP&UP Record Shares, and the MVP II Select Record Shares, representing a beneficial ownership of approximately 4.89% of the Issuers Common Stock. | |||||
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 1,501,361 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 1,501,361 |
J. | Paul Howard |
(a)/(b) | Amount beneficially owned:
In his capacity as a manager of each of Mediphase II LLC, Annex II LLC, DP&UP LLC, and Select Fund LLC, Mr. Howard may be deemed to be the beneficial owner of the MVP II LP Record Shares, the MVP II Annex Record Shares, the MVP DP&UP Record Shares, and the MVP II Select Record Shares, representing a beneficial ownership of approximately 4.89% of the Issuers Common Stock. | |||||
(c) | Number of shares as to which the person has: | |||||
(i) | Sole power to vote or to direct the vote: | 0 | ||||
(ii) | Shared power to vote or to direct the vote: | 1,501,361 | ||||
(iii) | Sole power to dispose or to direct the disposition of: | 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of: | 1,501,361 |
Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
There are no am endments to Item 6 of the Original Filing.
13G/A
CUSIP No. 88165N105 | Page 17 of 19 Pages |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. |
Not Applicable.
Item 8. | Identification and Classification of Members of the Group. |
Not Applicable.
Item 9. | Notice of Dissolution of Group. |
Not Applicable.
Item 10. | Certifications. |
Not Applicable. This Amendment No. 1 to Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d-1(c).
13G/A
CUSIP No. 88165N105 | Page 18 of 19 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 13, 2015 | MEDIPHASE VENTURE PARTNERS II LIMITED PARTNERSHIP | |||||||
BY: | MEDIPHASE II LLC, ITS GENERAL PARTNER | |||||||
BY: | /s/ PAUL HOWARD | |||||||
PAUL HOWARD | ||||||||
MANAGER | ||||||||
MEDIPHASE VENTURE PARTNERS II (ANNEX FUND) LIMITED PARTNERSHIP | ||||||||
BY: MEDIPHASE II (ANNEX FUND) LLC, ITS GENERAL PARTNER | ||||||||
BY: | /s/ PAUL HOWARD | |||||||
PAUL HOWARD | ||||||||
MANAGER | ||||||||
MEDIPHASE VENTURE PARTNERS (DP&UP) LIMITED PARTNERSHIP | ||||||||
BY: MEDIPHASE (DP&UP) LLC, ITS GENERAL PARTNER | ||||||||
BY: | /s/ PAUL HOWARD | |||||||
PAUL HOWARD | ||||||||
MANAGER | ||||||||
MEDIPHASE VENTURE PARTNERS II (SELECT FUND) LIMITED PARTNERSHIP | ||||||||
BY: MEDIPHASE II (SELECT FUND) LLC, ITS GENERAL PARTNER | ||||||||
BY: | /S/ PAUL HOWARD | |||||||
PAUL HOWARD | ||||||||
MANAGER | ||||||||
MEDIPHASE II LLC | ||||||||
BY: | /s/ PAUL HOWARD | |||||||
PAUL HOWARD | ||||||||
MANAGER |
13G/A
CUSIP No. 88165N105 | Page 19 of 19 Pages |
MEDIPHASE II (ANNEX FUND) LLC | ||
BY: | /s/ PAUL HOWARD | |
PAUL HOWARD MANAGER | ||
MEDIPHASE (DP&UP) LLC | ||
BY: | /s/ PAUL HOWARD | |
PAUL HOWARD MANAGER | ||
MEDIPHASE II (SELECT FUND) LLC | ||
BY: | /s/ PAUL HOWARD | |
PAUL HOWARD MANAGER | ||
/S/ LAWRENCE MILLER | ||
LAWRENCE MILLER | ||
/s/ PAUL HOWARD | ||
PAUL HOWARD |